电邮这篇文章 Use of a combination of docetaxel (Tautax and Taxotere) and etoposide plus prednisolone versus docetaxel monotherapy in the treatment of patients with hormone-resistant prostate cancer
- 作者: Gritskevich AA1, Medvedev VL1, Rusakov IG1, Bystrov SV1, Gritskevich AA1, Medvedev VL1, Rusakov IG1, Bystrov SV1
-
隶属关系:
- 期: 卷 16, 编号 2 (2011)
- 页面: 28-32
- 栏目: Articles
- ##submission.dateSubmitted##: 22.07.2020
- ##submission.datePublished##: 15.04.2011
- URL: https://rjonco.com/1028-9984/article/view/39840
- DOI: https://doi.org/10.17816/onco39840
- ID: 39840
如何引用文章
全文:
详细
The efficacy and safety of a combination of docetaxel and etoposide plus prednisolone versus docetaxel monotherapy were studied in patients with hormone-resistant prostate cancer.
The patients were divided into 2 groups: 1) 24 patients received docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day; 2) 21 patients used docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day + intravenous etoposide 100 mg/m2 on days 1 to 5. The patients' age ranged from 45 to 81 years (mean age 64.9 years). The study has shown that docetaxel monotherapy has benefits in terms of treatment response duration, overall survival, and satisfactory therapy tolerability.
The patients were divided into 2 groups: 1) 24 patients received docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day; 2) 21 patients used docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day + intravenous etoposide 100 mg/m2 on days 1 to 5. The patients' age ranged from 45 to 81 years (mean age 64.9 years). The study has shown that docetaxel monotherapy has benefits in terms of treatment response duration, overall survival, and satisfactory therapy tolerability.
参考
- Русаков И. Г., Алексеев Б. Я. // Соврем. онкол. - 2004. - Т. 6, № 3. - С. 116-121.
- Чиссов В. И. Онкологическая заболеваемость и смертность. - М., 2008.
- Abrahamson Per-Anders. // Eur. Urol. - 2003. - Suppl. 2. - P. 1-2.
- Benson R., Hartley-Asp B. // Cancer Invest. - 1990. - Vol. 8. - P. 375-380.
- Dahllof B., Billstrom A., Cabral F., Hartley-Asp. B. // Cancer Res. - 1993. - Vol. 53. - P. 4573-4581.
- Earhart R. H. // Semin. Oncol. - 1999. - Vol. 26. - P. 8-13.
- Eisenberger M. A., Simon R., O'Dwyer P. J. et al. // J. Clin. Oncol. - 1985. - Vol. 3. - P. 827-841.
- Garnick M. B. // Ann. Intern. Med. - 1993. - Vol. 118. - P. 804-818.
- Heidenreich A., Schrader A. J. // EAU Update Ser. 1. - 2003. - P. 40-50.
- Iversen P. // Eur. Urol. - 2000. - Suppl. 2. - P. 3-8.
- Petrylak D. P., Tangen C. M., Hussain M. H. et al. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1515-1520.
- Tannock I. F., de Wit R., Berry W. J. et al. // N. Engl. Med. - 2004. - Vol. 351. - P. 1502-1512.
- Yagoda A., Petrylak D. // Cancer. - 1993. - Vol. 71. - P. 1098-1109.
补充文件
